Protagonist Therapeutics (PTGX) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 17, 2026, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials online or request copies before voting.

Voting matters and shareholder proposals

• Election of two Class I director nominees to serve until the 2029 annual meeting.

• Advisory vote to approve executive compensation for named executive officers.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Approval of the 2026 Equity Incentive Plan.

• Board is not aware of any other matters expected at the meeting but reserves the right to vote on additional items if presented.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director nominees and compensation matters.